As CEO of Cellanyx Diagnostics, Ashok is currently advancing a novel live cell biopsy-on-a-chip technology. As reported by Boston Business Journal, Urology Today and The Wall Street Journal’s Venture Wire, Cellanyx provides a first-in-class live cell phenotypic cancer diagnostic platform to aid clinical decision making and reduce repeat biopsies. The Cellanyx live-cell biomarker platform has potential use in cancer diagnosis, risk stratification and prognostic applications in a wide range of human cancers and as a research tool for biomarker and drug development.
Ashok developed Cellanyx’s core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital.
Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors. In collaboration with Cellanyx’s Scientific Advisory Board, Ashok has successfully initiated and currently leads five diagnostic clinical programs.
Ashok enjoys collaborating with executives, clinicians, engineers, and scientists to advance our understanding of biological processes, promote discovery, develop clinically actionable technologies, and create sustainable clinical and therapeutic value.
Ashok began his scientific training at the National Institutes of Health (NIH). Advised by two Nobel Laureates, Ashok received his S.B. in Biology from MIT and Ph.D. from Columbia University. Raised in Potomac, Maryland, Ashok is a lifelong tennis player and new father, appreciating their respective emphases on preparation, dedication, stamina, and good hands.